Clinical Trials
82 trialsLN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
M.D. Anderson Cancer Center
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
REPOTHYROID-II
Radboud University Medical Center
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
National Cancer Center Hospital East
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
City of Hope Medical Center
DETERMINE
Cancer Research UK
TROPION
Zhejiang Provincial People's Hospital
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
AKIR001
Karolinska University Hospital
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
M.D. Anderson Cancer Center
DETERMINE
Cancer Research UK
NEO-COMBATXL
UNC Lineberger Comprehensive Cancer Center
Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer
Northwestern University
IMMUNORARE5
Hospices Civils de Lyon
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
Saint Petersburg State University, Russia
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
TATC
National Health Research Institutes, Taiwan
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
AffyImmune Therapeutics, Inc.
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
Alliance for Clinical Trials in Oncology
SETHY
Grupo Espanol de Tumores Neuroendocrinos
Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
Fujian Medical University
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
Saint Petersburg State University, Russia
ANAPLAST-NEO
Saint Petersburg State University, Russia
Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3
National Taiwan University Hospital
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Dana-Farber Cancer Institute
NEO-ATACT
Leiden University Medical Center
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation
Shanghai Henlius Biotech
ITCO
University of Roma La Sapienza
Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
Power Life Sciences Inc.
ATCEU
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Novartis
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
National Cancer Institute (NCI)
Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients
National Taiwan University Hospital
iNATT
Velindre NHS Trust
PIONEER
SpeciCare
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
Fore Biotherapeutics
Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)
Taizhou Hanzhong biomedical co. LTD
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
Daiichi Sankyo
HOPE
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan